FMP

FMP

Enter

SLRX - Salarius Pharmaceuti...

photo-url-https://images.financialmodelingprep.com/symbol/SLRX.png

Salarius Pharmaceuticals, Inc.

SLRX

NASDAQ

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.

2.69 USD

0.07 (2.6%)

Latest SLRX News

InvestorPlace

Jul 23, 2024

Why Is Salarius Pharmaceuticals (SLRX) Stock Up 90% Today?

Genomic therapeutic specialist Salarius Pharmaceuticals (NASDAQ: SLRX ) screamed higher Tuesday, with shares gaining 160% before paring back some of the gains to around 90%. Although no catalyst is apparent, the biotechnology firm revealed details about its at-the-market (ATM) offering recently.

Read More

Market Watch

May 9, 2023

Salarius Pharmaceuticals stock soars premarket after FDA lifts partial clinical hold on trial of treatment for rare form of cancer that starts in chil...

Salarius Pharmaceuticals Inc.'s stock SLRX soared 33% in premarket trade Tuesday after the company said the U.S. Food and Drug Administration has lifted a partial clinical hold on a trial of a treatment for Ewing sarcoma, a rare and deadly form of cancer that occurs in bones or the soft tissue around bones. The treatment called seclidemstat, was being reviewed in a Phase 1/2 trial and had previously been granted Fast Track Designation, Orphan Drug Designation and Rare Pediatric Disease Designati...

Read More

GlobeNewsWire

Apr 4, 2023

Salarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational Conference

HOUSTON, April 04, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today announced that management will present at the Diamond Equity Research Emerging Growth Invitational virtual investor conference taking place Wednesday, April 5th.

Read More

GlobeNewsWire

Jan 19, 2023

Salarius Pharmaceuticals to Present SP-3164 Targeted Protein Degrader Preclinical Data at the Inaugural Molecular Glue Drug Development Summit

Dr. Aundrietta Duncan to discuss mechanism of action and SP-3164 activity in cancer models

Read More

GlobeNewsWire

Oct 19, 2022

Salarius Pharmaceuticals to Present SP-3164 at the 5th Annual Targeted Protein Degradation Conference

HOUSTON, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today announced that Daniela Santiesteban, Ph.D., Salarius' director of targeted protein degradation development, will be presenting at the 5th Annual Targeted Protein Degradation Conference being held October 25-28 in Boston. Dr. Santiesteban...

Read More

GlobeNewsWire

Sep 20, 2022

Salarius Pharmaceuticals to Present at the 2022 Ladenburg Thalmann Healthcare Conference

HOUSTON, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company developing medicines for patients fighting cancer and in need of new treatment options, today announced that management will present at the 2022 Ladenburg Thalmann Healthcare Conference being held on September 29th in New York City at the Sofitel Hotel. David Arthur, chief executive officer, will deliver a corporate presentation and participate in a “fireside chat...

Read More

Seeking Alpha

Aug 8, 2022

Salarius Pharmaceuticals, Inc.'s (SLRX) CEO David Arthur on Q2 2022 Results - Earnings Call Transcript

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX ) Q2 2022 Earnings Conference Call August 8, 2022 11:00 AM ET Company Participants Kim Golodetz - Senior Vice President, Principal, LHA Investor Relations David Arthur - Director and CEO Mark Rosenblum - Chief Financial Officer Dr. Daniela Santiesteban - Director, Protein Degradation, Development Conference Call Participants Ahu Demir - Ladenburg Operator Welcome to the Salarius Pharmaceuticals Second Quarter 2022 Financial Results and Business Update ...

Read More

Proactive Investors

Aug 2, 2022

VolitionRx Limited inks R&D collaboration deals with Xenetic Biosciences and Salarius Pharmaceuticals in push to develop cancer treatments

VolitionRx (NYSE-A:VNRX) Limited has inked a pair of research and development collaborations that will develop targeted, adoptive cell therapies to treat cancer and help advance a drug designed to treat solid and hematologic cancers. First off, the company will collaborate with Xenetic Biosciences (NASDAQ:XBIO) Inc to evaluate the potential combination of Volition's Nu.Q NETs Test and Xenetic's DNase-Armored CAR T platform to develop proprietary adoptive cell therapies potentially targeting mult...

Read More

GlobeNewsWire

Jul 29, 2022

Salarius Pharmaceuticals to Host Second Quarter 2022 Financial Results and Business Update Conference Call on Monday, August 8, 2022

Conference Call and Live Audio Webcast Scheduled for 11:00 a.m. ET Conference Call and Live Audio Webcast Scheduled for 11:00 a.m. ET

Read More

GlobeNewsWire

May 18, 2022

Salarius Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference

HOUSTON, May 18, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other solid and hematological cancers, today announced that David Arthur, CEO of Salarius Pharmaceuticals, will be virtually presenting at the H.C. Wainwright Global Investment Conference being held on May 23-26, 2022.

Read More
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep